Bioasis and CEO Deborah Rathjen (DR) were quite active on Twitter today getting ready for BIO 2019 (June 3-6) by promoting xB3-001 (Trastuzumab/Herceptin) for HER2+ Brain Metastases, xB3-002 (Bevacizumab) for Glioblastoma, xB3-Doxorubicin for Intracranial Tumors, xB3-IL1RA for Inflammatory Conditions and Pain, xB3-007 (Cerezyme) for Gaucher's Type 2.

https://twitter.com/BioasisUS

https://twitter.com/rathjen3

Bioasis - "Bioasis will be at BIO next week, please reach out to learn more about our exciting technology and pipeline."

DR - "BiOasis will be at BIO2019 in the Partnering Forum talking about our proprietary BBB delivery technology - the solution to your brain drug delivery problem."

DR - "#BIO2019 BiOasis is presenting a new licensing opportunity - a proprietary drug candidate for the treatment of pain and inflammatory conditions from our BBB drug delivery platform." 

DR - "#BIO2019 Meet with us to learn about our growing pipeline to treat brain cancers. A pipeline based on facilitating the transport of approved, well established medicines into the brain."

DR - "Come meet with the BiOasis team and learn more about of BBB drug delivery platform, our pipeline and our partnerships."

BearDownAZ